SN BioScience released a result of the first clinical trial on Nanoparticle-based anticancer therapy at ESMO(European Society for Medical Oncology)
SN Bioscience (CEO Park Yung-hwan) released the phase 1 clinical trial result on SNB-101, a new anticancer medicine pipeline, at ...